Products
Online Inquiry
CCT196969
Cat. No.:
0225LY-1108
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
CCT196969 represents a novel, orally bioavailable pan-RAF inhibitor that additionally suppresses the p38 MAPKs, LCK, and SRC.
Synonym:
1163719-56-9; 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea; 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea; 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-(2-fluoro-4-((3-oxo-4H-pyrido(2,3-b)pyrazin-8-yl)oxy)phenyl)urea; 3-(5-tert-butyl-2-phenylpyrazol-3-yl)-1-[2-fluoro-4-({3-oxo-5H-pyrido[2,3-b]pyrazin-8-yl}oxy)phenyl]urea
CAS No.:
1163719-56-9
Compound CID:
42628843
Formula:
C27H24FN7O3
Formula Weight:
513.52
Specification
Targets&IC50:
B-Raf (V600E): 0.04 μM; Lck: 0.02 μM; Raf: 0.01 μM; BRAF: 0.1 μM; Src: 0.03 μM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CCT196969 can be used in melanoma research to investigate the simultaneous inhibition of mutant B-RAF and Src kinases.
Library Information
Target:
Raf; Src
Receptor:
C-RAF; Src
Pathways:
Angiogenesis; MAPK; Tyrosine kinase/adaptors
Plate Number:
AOCL-15
Plate Location:
c4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
127.5 mg/mL; 248.29 mM
ALogP:
4.782
HBA_Count:
6
HBD_Count:
3
Rotatable Bond:
6
